Delving into the Latest Updates on HRS-6208 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Shandong Suncadia Medicine Co., Ltd.

Active Organization

Shanghai Hengrui Pharmaceutical Co., Ltd.Shandong Suncadia Medicine Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的： 1. 评价HRS-6208在晚期实体瘤患者中的安全性和耐受性。 2. 确定HRS-6208单药在晚期实体瘤患者中的剂量限制性毒性（DLT），确定最大耐受剂量（MTD）和II期临床研究推荐剂量（RP2D）。次要目的： 1. 评估HRS-6208在晚期实体瘤患者中的药代动力学（PK）特征。 2. 初步评价HRS-6208食物效应。 3. 初步评价HRS-6208在晚期实体瘤患者中的疗效。

[Translation]

Primary objectives: 1. To evaluate the safety and tolerability of HRS-6208 in patients with advanced solid tumors. 2. To determine the dose-limiting toxicity (DLT) of HRS-6208 monotherapy in patients with advanced solid tumors, and to determine the maximum tolerated dose (MTD) and recommended dose (RP2D) for Phase II clinical studies. Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of HRS-6208 in patients with advanced solid tumors. 2. To preliminarily evaluate the food effect of HRS-6208. 3. To preliminarily evaluate the efficacy of HRS-6208 in patients with advanced solid tumors.

Start Date17 Dec 2024

Sponsor / Collaborator

Shanghai Hengrui Pharmaceutical Co., Ltd.

[+1]

ChiCTR2400093413

/ SuspendedPhase 1IIT

A Phase I Clinical Study of the Safety,Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6208 Monotherapy in Patients With Advanced Solid Tumors

Start Date09 Dec 2024

Sponsor / Collaborator

West China Hospital

100 Clinical Results associated with HRS-6208

Login to view more data

100 Translational Medicine associated with HRS-6208

Login to view more data

100 Patents (Medical) associated with HRS-6208

Login to view more data

100 Deals associated with HRS-6208

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	China	Shanghai Hengrui Pharmaceutical Co., Ltd.	17 Dec 2024
Advanced Malignant Solid Neoplasm	Phase 1	China	Shandong Suncadia Medicine Co., Ltd.	17 Dec 2024